Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35030335

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Feb
First author
Kang YK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Palliat Med. 2022 Oct;11(10):3371-3375. doi: 10.21037/apm-22-851.
    note
    Source null
    related pmid
    36267012
    relationship
    Comment in

Authors and identifiers

  1. name
    Kang YK
    type
    Author
  2. name
    Chen LT
    type
    Author
  3. name
    Ryu MH
    type
    Author
  4. name
    Oh DY
    type
    Author
  5. name
    Oh SC
    type
    Author
  6. name
    Chung HC
    type
    Author
  7. name
    Lee KW
    type
    Author
  8. name
    Omori T
    type
    Author
  9. name
    Shitara K
    type
    Author
  10. name
    Sakuramoto S
    type
    Author
  11. name
    Chung IJ
    type
    Author
  12. name
    Yamaguchi K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kang YK
    type
    Author
  2. name
    Chen LT
    type
    Author
  3. name
    Ryu MH
    type
    Author
  4. name
    Oh DY
    type
    Author
  5. name
    Oh SC
    type
    Author
  6. name
    Chung HC
    type
    Author
  7. name
    Lee KW
    type
    Author
  8. name
    Omori T
    type
    Author
  9. name
    Shitara K
    type
    Author
  10. name
    Sakuramoto S
    type
    Author
  11. name
    Chung IJ
    type
    Author
  12. name
    Yamaguchi K
    type
    Author
bibliography ids
  1. nci-bib-da9f76c7722bfb32f9745ead
book metadata
content sha256
8c5a7d4d37cc3f901971a9cdc6f3035dfb7fb19c8331e21c3d941e7b5ce30280
document type
citation
dois
  1. 10.1016/S1470-2045(21)00692-6
electronic publication date
display
2022 Jan 11
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35030335
immutable id
pubmed:35030335@8c5a7d4d37cc3f901971a9cdc6f3035dfb7fb19c8331e21c3d941e7b5ce30280
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
234-247
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Palliat Med. 2022 Oct;11(10):3371-3375. doi: 10.21037/apm-22-851.
    note
    Source null
    related pmid
    36267012
    relationship
    Comment in
outcomes validated
false
pmid
35030335
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
6b9905688f73c76aa40d4cc6ff6483197bb92bad8fa86f6967a16d6412b5f9f6
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Feb
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35030335/
title
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice